AI assistant
NYRADA INC. — Capital/Financing Update 2021
Jan 6, 2021
65469_rns_2021-01-06_25552422-bbbd-499d-815b-8dd375aacb29.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [596 x 114] intentionally omitted <==
7 January 2021
Sydney, Australia
Release of Securities from Escrow
Sydney, 7 January 2021: Nyrada Inc (ASX: NYR) confirms that as advised in its Appendix 2A in accordance with Listing Rule 3.10A announced to the ASX on 2 December 2020, that the following securities will be released from escrow on 9 January 2021.
| ASX Code | Number | Class |
|---|---|---|
| NYR | 86,901 | Chess Depositary Interests |
The Company noted that these securities are already listed securities and therefore there is no requirement to apply for their quotation after the end of the escrow period.
About Nyrada Inc
Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular, neurological, and inflammatory/autoimmune diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.
-ENDS-
Authorised by Mr John Moore, Non-Executive Chairman, on behalf of the Board.
Investor & Corporate Enquiries: Prue Kelly T: 0459 022 445 E: [email protected]
David Franks
T: 02 8072 1400
Media Enquiries:
Catherine Strong Citadel-MAGNUS T: 02 8234 0111 E: [email protected]
Nyrada Inc. Suite 3, Level 4, 828 Pacific Highway GORDON, NSW 2072
Nyrada Inc. ARBN 625 401 818